KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
IPO Year:
Exchange: NASDAQ
Website: kempharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 9/15/2022 | $20.00 | Buy | Canaccord Genuity |
| 1/31/2022 | $10.00 → $11.00 | Neutral → Buy | HC Wainwright & Co. |
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwa
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare disea
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2023 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company's Annual Meeting — Richard W. Pascoe, David S. Tier
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on March 7, 2023. Additionally, in
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLDSymposium™ 2023, an annual research conference dedicated to lysosomal diseases. WORLDSymposium 2023 is held February 22-26, 2023, in Orlando, Florida. Arimoclomol is an orally-delivered, first-in-class investigational product candidate being developed as a
New name, Greek for "zebra," is the internationally-recognized symbol for the rare disease community Branding reflects Company's commitment to making rare disease therapies available through its research, development, and commercialization efforts The Company's common shares will trade on The Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting on or about March 1, 2023 CELEBRATION, Fla., Feb. 22, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) ("KemPharm," or the "Company"), announced today that it changed its name to Zevra Therapeutics, Inc. ("Zevra"). This name change reflects the Company's intensified focus and dedication to developing transformational, pati
Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs. Both positions are newly created at KemPharm and continue a series of enhanceme
CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for 2023. The full text of the letter follows. A MESSAGE FROM RICH PASCOE, OUR CHIEF EXECUTIVE OFFICER Dear Fellow Shareholders: This is a very exciting time in the growth of KemPharm and our strategi
CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced its partnership with the Hypersomnia Foundation, which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia (IH) and related sleep disorders. IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness. It is estimated that appro
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm's leadership team since the early days of
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)